mRNA levels of CD31, CD144, CD146 and von Willebrand factor do not serve as surrogate markers for circulating endothelial cells

Journal:Thrombosis and Haemostasis
ISSN:0340-6245
DOI:http://dx.doi.org/10.1160/TH09-08-0594
Issue:2010: 104/2 (Aug) pp. 191– 419
Pages:318-326

mRNA levels of CD31, CD144, CD146 and von Willebrand factor do not serve as surrogate markers for circulating endothelial cells

M. H. Strijbos (1), B. A. van Krimpen (1), R. Debets (1), J. Kraan (1), S. Sleijfer (1), J. W. Gratama (1), C. H. J. Lamers (1)

(1) Laboratory of Translational Tumorimmunolgy, Department of Medical Oncology, Erasmus University Medical Center – Daniel den Hoed Cancer Center, Rotterdam, The Netherlands

Summary

Circulating endothelial cells (CEC) are considered a promising marker to determine the extent of vascular damage. However, currently available and validated CEC enumeration assays are laborious, time consuming and costly, which limits their clinical utility. Here, we evaluated the feasibility of quantifying mRNA levels of the endothelium-associated markers CD31, CD144, CD146 and von Willebrand factor (vWf) in peripheral blood (PB) of healthy donors, patients, and human umbilical veins by real-time reverse transcriptase polymerase chain reaction (RT-PCR) and their use as surrogate markers for CEC. Whole blood samples and CD146+ cell-enriched fractions were assessed for mRNA and protein expression of CD31, CD144, CD146 and vWf by RT-PCR and flow cytometry, respectively. We showed the feasibility to detect endothelial mRNA isolated from HUVEC numbers as low as 10. However, no endothelial mRNA could be measure in whole blood samples, and only low levels of CD31 and CD146 mRNA were detected in suspensions of isolated CEC with numbers up to 4,450 CEC per sample. We conclude that mRNA levels of CD31, CD144, CD146 and vWf in whole blood as detected by real time RT-PCR cannot be used as biomarkers for end-stage endothelial cells such as CEC.

Keywords

Circulating endothelial cells, vascular damage, RT-PCR, endothelial markers

DOI

http://dx.doi.org/10.1160/TH09-08-0594

You may also be interested in...

1.

Laura Vroling1, Yuana Yuana1, Gerrit Jan Schuurhuis2, Victor W. M. van Hinsbergh3, Chad Gundy4, Richard de Haas1, Hester van Cruijsen1, Epie Boven1, Klaas Hoekman1, Henk J. Broxterman1

Thrombosis and Haemostasis 2007 98 2: 440-450

http://dx.doi.org/10.1160/TH07-03-0225

2.

Patrick K. Y. Goon, Christopher J. Boos, Paul S. Stonelake, Andrew D. Blann, Gregory Y. H. Lip

Thrombosis and Haemostasis 2006 96 1: 45-52

http://dx.doi.org/10.1160/TH06-04-0185

3.

Michiel H. Strijbos1, Chandra Rao2, Paul I. M. Schmitz3, Jaco Kraan1, Cor H. Lamers1, Stefan Sleijfer1, Leon W. M. M. Terstappen2, Jan W. Gratama1

Thrombosis and Haemostasis 2008 100 4: 642-647

http://dx.doi.org/10.1160/TH08-02-0122



Articles

You've 242 Article(s) in your Basket.

TH 107.5

Clinical Focus on GPIIb/IIIa inhibitors: In the May issue of Thrombosis and Haemostasis Armstrong...

TH 107.4

The April 2012 issue of Thrombosis and Haemostasis TH 107.4 is a Theme Issue by A. Schober, T....

Thrombosis and Haemostasis official organ of Spanish Society for Thrombosis and Haemostasis

Thrombosis and Haemostasis, founded in 1957, has become the official organ of the Spanish Society...